Anzeige
Mehr »
Sonntag, 21.06.2026 - Börsentäglich über 12.000 News
Quantum X Labs: Steigt die Aktie auch durch das Amazon-AWS-Fieber?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A40EDR | ISIN: US46489V3024 | Ticker-Symbol: AAJ0
Tradegate
19.06.26 | 10:40
2,524 Euro
-1,64 % -0,042
Branche
Gesundheitswesen
Aktienmarkt
Sonstige
1-Jahres-Chart
PERSPECTIVE THERAPEUTICS INC Chart 1 Jahr
5-Tage-Chart
PERSPECTIVE THERAPEUTICS INC 5-Tage-Chart
RealtimeGeldBriefZeit
2,5582,58420.06.
2,5162,61619.06.

Aktuelle News zur PERSPECTIVE THERAPEUTICS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
03.06.Perspective Therapeutics, Inc.: Perspective Therapeutics Expands Therapeutic Focus Areas; First Patient Dosed with [212Pb]VMT-a-NET in the Meningioma Cohort of a Phase 1/2a Study131SEATTLE, June 03, 2026 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. ("Perspective," the "Company," "we," "us," and "our") (NYSE AMERICAN: CATX), a radiopharmaceutical development company pioneering...
► Artikel lesen
27.05.Perspective Therapeutics, Inc. - 8-K, Current Report2
21.05.Perspective Therapeutics, Inc.: Perspective Therapeutics to Present Data from All Clinical Programs at the 2026 ASCO Annual Meeting, including Findings from [212Pb]VMT01 in Melanoma3
18.05.Perspective Therapeutics doses first patients in two trial cohorts2
18.05.Perspective Therapeutics, Inc.: Perspective Therapeutics Announces First Patients Dosed in New Cohorts of Two Ongoing Phase 1/2a Studies261SEATTLE, May 18, 2026 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. ("Perspective," the "Company," "we," "us," and "our") (NYSE AMERICAN: CATX), a radiopharmaceutical development company pioneering...
► Artikel lesen
PERSPECTIVE THERAPEUTICS Aktie jetzt für 0€ handeln
12.05.Perspective Therapeutics: RBC Kapital sieht erhebliches Kurspotenzial trotz Datenverzögerung4
12.05.RBC Capital reiterates Outperform on Perspective Therapeutics stock5
11.05.Perspective Therapeutics, Inc.: Perspective Therapeutics Provides Recent Business Highlights and Reports 1Q 2026 Results258Differentiated ²¹²Pb radiopharmaceutical platform designed to optimize tumor killing, safety, patient convenience and supply scalabilityThree clinical-stage oncology programs advancing across neuroendocrine...
► Artikel lesen
11.05.Perspective Therapeutics, Inc. - 10-Q, Quarterly Report-
11.05.Perspective Therapeutics, Inc. - 8-K, Current Report-
04.05.Perspective Therapeutics, Inc. - 8-K, Current Report1
24.04.Perspective Therapeutics, Inc.: Perspective Therapeutics to Provide Several Upcoming Corporate Updates484SEATTLE, April 24, 2026 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. ("Perspective" or the "Company") (NYSE AMERICAN: CATX), a radiopharmaceutical development company pioneering advanced treatments...
► Artikel lesen
20.04.Perspective Therapeutics reports interim trial results for NET therapy2
20.04.Perspective Therapeutics, Inc.: Perspective Therapeutics Presents Updated Interim Data of [212Pb]VMT-a-NET in Its Ongoing Phase 1/2a Clinical Trial at the 2026 AACR Annual Meeting2
20.04.Perspective Therapeutics, Inc. - 8-K, Current Report-
01.04.Perspective Therapeutics, Inc. - 8-K, Current Report1
23.03.H.C. Wainwright raises Perspective Therapeutics price target to $132
18.03.Jones Trading reiterates Perspective Therapeutics stock Buy rating4
17.03.Perspective Therapeutics, Inc.: Perspective Therapeutics Announces Acceptance of VMT-a-NET Data for Presentation at the AACR Annual Meeting 20265
17.03.Truist reiterates Buy on Perspective Therapeutics stock3
Weiter >>
45 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1